NCI IDIQ Contract for Genomic Characterization Centers
National Institutes of Health · NIH National Cancer Institute
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N91024R00001 in this department, oldest first.
- Jan 8, 2025Award NoticeINFINITY BIOLOGIX LLC · $150.0MOpen
- Jan 8, 2025Award NoticeSEQMATIC, LLC · $150.0MOpen
- Jan 8, 2025Award NoticeWashington University, The CAMPUS BOX 1054 ONE BROOKINGS DRIVE SAINT LOUIS MO 63130 USA · $150.0MOpen
- Jan 10, 2025Award NoticeNEW YORK GENOME CENTER, INC. · $150.0MOpen
- Jan 10, 2025Award NoticeUNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ADMINISTRATIVE OFFICE BUILDING, SUITE 2200 104 AIRPORT DRIVE, SUITE 2200, CB 1350 Chapel Hill NC 27599 USA · $150.0MOpen
- Jan 10, 2025Award NoticeUNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET FL 3 Los Angeles CA 90089 USA · $150.0MOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
Amendement 1: The purpose of Amendment 1 is to answer offerors' questions related to RFP # 75N91024R00001 and update Attachment 2 "Proposal Intent Response Form." The hour and date specified for receipt of offers remains unchanged: 2/26/2024 at 3:00 PM Eastern prevailing time.
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same NAICS 541380.
Single-winner award sizes (4): middle half $45K to $8.9M, median $103K; range $29K to $35.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AZENTA US INC | 1 | $35.0M | Dec 2, 2024 |
| NORGEN BIOTEK CORP | 1 | $157K | Sep 19, 2025 |
| CDI LABORATORIES INC | 1 | $50K | Mar 17, 2025 |
| HISTOSERV, INC | 1 | $29K | May 5, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Sep 19, 2025NORGEN BIOTEK CORP$157KQ--Small RNA characterization of urinary exosomes
- May 5, 2025HISTOSERV, INC$29KSignatures of aging outcomes
- Mar 17, 2025CDI LABORATORIES INC$50KCDI Laboratories HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis
- Dec 2, 2024AZENTA US INC$35.0MQ--Childhood Cancer Data Initiative (CCDI)
Competitive landscape
For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.